Biotek-snakken

	23/9 07:16 af ProInvestorNEWS	FDA greenlights Sanofi's Sarclisa in frontline multiple myeloma (link)
	23/9 05:28 af Fandel	Godmorgen...
	21/9 08:25 af ProInvestorNEWS	FDA Approves Zevra Therapeutics' MIPLYFFA For Treatment Of Niemann-Pick Disease Type C (link)
	21/9 05:32 af Fandel	Godmorgen...
	20/9 06:01 af ProInvestorNEWS	Ascendis Pharma Prices Public Offering Of 2 Mln ADSs At $150.00/ADS (link)
	20/9 06:00 af ProInvestorNEWS	Tectonic Therapeutics Announces Positive Phase 1a Results For TX45 In Treating Group 2 PH-HFpEF (link)
	20/9 06:00 af ProInvestorNEWS	ELAN : FDA Oks Zenrelia, Once-Daily Oral JAK Inhibitor For Dogs With Allergic And Atopic Dermatitis (link)
	19/9 18:37 af Henrikhot	(link) Saniona Receives Regulatory Approval for SAN711 Biomarker Study
	19/9 18:34 af Henrikhot	Saniona kommenterar godkännandet att inleda epilepsistudie (link)
	19/9 09:39 af exitnu	"Handel i betalda tecknade units (”BTU”): 20 augusti – 20 september 2024."
	19/9 09:38 af exitnu	Ascelia Pharma BTU: sidste handelsdag nu på fredag :-)
	19/9 06:03 af ProInvestorNEWS	Incyte: Phase 2 Trial Results Of Niktimvo In Chronic Graft-Versus-Host Disease Meet Primary Goal (link)
	17/9 06:11 af ProInvestorNEWS	I-Mab Reports Promising Results From Phase 1 Study Of Givastomig In Gastric Cance (link)
	16/9 11:14 af ProInvestorNEWS	Johnson & Johnson Reports Promising Interim Data From Phase 2 SunRISe-4 Study (link)
	16/9 08:38 af exitnu	"På våra prognoser och antagande om teckning av optionsprogrammet bedömer vi att Ascelia kommer att klara sig omkring 18-24 månader innan ytterligare kapital eventuellt kommer behöva skjutas till."
	16/9 08:37 af exitnu	Penser Access & Future by Carnegie: Ascelia Pharma: Kassan fylld (link) Aktiekurs 2,1 kr - Motiverat värde 5,0 - 7,0 kr.
	14/9 12:31 af ProInvestorNEWS	Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? (link)
	14/9 12:29 af ProInvestorNEWS	Sutro Announces Updated Data From Phase 1b Study Of Luvelta Combination In Epithelial Ovarian Cancer (link)
	14/9 11:49 af ProInvestorNEWS	Bicycle Therapeutics Reveals Updated Clinical Results Across Oncology Pipeline(link)
	14/9 11:48 af ProInvestorNEWS	Pfizer's BRAFTOVI + MEKTOVI Delivers Long-Term Benefits In BRAF V600E-Mutant NSCLC (link)
	14/9 10:43 af bibob	Ascelia Pharma. (link)
	14/9 06:55 af Fandel	Godmorgen...
	13/9 22:36 af Occam	Ja. Det ville være finere, hvis investorerne var mere ligestillede ift. informationer. - Nå, Biontech sluttede dagen med +17,5%, hele ugen med +33,5%.
	13/9 21:00 af peter12	Der er gange i flere biotek i aften pga ESMO (link)

	13/9 17:46 af Occam	Biontech +11% på Nasdaq. Efter to timer er omsætningen 4 gange en normal dags.
	13/9 14:36 af exitnu	Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients (link)
	13/9 14:35 af exitnu	Moberg Pharma nede med minus 57% i dag ...
	13/9 06:36 af ProInvestorNEWS	Cidara Eliminates 30% Of Workforce To Prioritize Clinical Development Of CD388; Stock Down (link)
	13/9 06:26 af ProInvestorNEWS	Immuneering Reports Positive Initial Data For IMM-1-104 In Phase 2a Pancreatic Cancer Trial;stock Up (link)
	13/9 06:24 af ProInvestorNEWS	FDA Oks Genentech's Tecentriq Hybreza As First & Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy (link)
	13/9 06:02 af Fandel	Godmorgen...
	13/9 05:49 af Helge Larsen/PI-redaktør	Godmorgen :-)
	12/9 14:19 af Aps invest	Board member purchases shares in Acarix I dag kl. 14:02 ∙ MFN Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces that Dr. Tony Daz, Board member of Acarix, purchased 2,000,600 shares in the company between September 9 and September 11 at an average price of USD 0.031 per share. His total ownership amounts to 2,000,600 shares. "I have great faith in the company and its product. The Acarix system is a disruptive technology to rapidly rule out CAD in a cost-effective way and
	12/9 06:04 af ProInvestorNEWS	J&J's TREMFYA Receives FDA Approval For Moderately To Severely Active Ulcerative Colitis In Adults (link)
	12/9 06:03 af ProInvestorNEWS	Ascendis Pharma Gets U.S. Orphan Drug Exclusivity For YORVIPATH In Adult Hypoparathyroidism (link)
	12/9 06:03 af ProInvestorNEWS	Innovent Biologics : Phase 3 Trial Results Of Mazdutide In Type 2 Diabetes Presented At EASD 2024 (link)
	12/9 06:00 af Helge Larsen/PI-redaktør	Godmorgen :-)
	11/9 07:31 af LP90	Godmorgen :-)
	11/9 06:02 af ProInvestorNEWS	BridgeBio's BBP-812 Canavan Disease Gene Therapy Receives FDA RMAT Designation (link)
	11/9 06:01 af ProInvestorNEWS	2 Biotech Stocks To Watch In September 2024 (link)
	10/9 06:46 af ProInvestorNEWS	ArriVent Announces Positive Phase 1b Data For Firmonertinib In NSCLC With EGFR PACC Mutations (link)
	10/9 06:43 af Fandel	Godmorgen...
	10/9 06:37 af ProInvestorNEWS	AstraZeneca :Dato-DXd Fails To Significantly Improve Overall Survival In Phase III Lung Cancer Trial (link)
	10/9 06:37 af ProInvestorNEWS	Regeneron's Five-Year Phase 3 Trial Shows Durable Survival Benefit Of Libtayo In PD-L1 High NSCLC (link)
	9/9 19:38 af Jazzz	Teva.. kunne ikke ha sagt det bedre.
	9/9 19:38 af Jazzz	(link)
	9/9 06:09 af ProInvestorNEWS	Summit's bispecific halves risk of disease progression, death versus Keytruda in lung cancer study (link)
	8/9 17:20 af Bjæssing09	Jazz, er ret sikker på, at vi sagtens kan se 8-10 SEK på en godkendelse af Tesofensine, hvilket vil give en fast indtjening fremover og her hedmed noget tryghed for investorerne og kommer der 1-2 partneraftaler her i 2024, ja så er vi i min verden forbi 12 SEK og også højere. Deres pipeline er helt fantastisk som du selv skriver.
	8/9 06:52 af Fandel	Godmorgen...
	6/9 18:32 af Jazzz	Jeg har været investeret i dem i mange år iøvrigt..